Perampanel 1 week titration + Perampanel 2 week titration + Perampanel 4mg + Placebo

ApprovedTerminated
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Epilepsy

Conditions

Epilepsy

Trial Timeline

Oct 20, 2021 → May 1, 2023

About Perampanel 1 week titration + Perampanel 2 week titration + Perampanel 4mg + Placebo

Perampanel 1 week titration + Perampanel 2 week titration + Perampanel 4mg + Placebo is a approved stage product being developed by Eisai for Epilepsy. The current trial status is terminated. This product is registered under clinical trial identifier NCT04417907. Target conditions include Epilepsy.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy were approved

Approved (20) Terminated (5) Active (0)

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04417907ApprovedTerminated

Competing Products

20 competing products in Epilepsy

See all competitors
ProductCompanyStageHype Score
perampanelEisaiPhase 2
35
LacosamideUCBPhase 3
40
Zonisamide + PlaceboEisaiPhase 3
32
ZonegranEisaiApproved
35
perampanel + perampanelEisaiPhase 1
29
Perampanel + PlaceboEisaiApproved
35
perampanelEisaiApproved
35
E2007 + PlaceboEisaiPhase 2
35
Placebo + RufinamideEisaiPhase 3
40
E2007 (perampanel) + PlaceboEisaiPhase 2
35
Perampanel Oral TabletEisaiApproved
43
perampanelEisaiPhase 3
40
PerampanelEisaiPre-clinical
26
Zonisamide + CarbamazepineEisaiPhase 3
40
PerampanelEisaiApproved
43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
29
PerampanelEisaiPhase 2
35
Zonisamide + PlaceboEisaiPhase 3
40
zonisamide low dose group + zonisamide high dose groupEisaiApproved
43
E2007 + E2007 + PlaceboEisaiPhase 2
35